Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 3, 2026
Two people walk into the same clinic. Same age, same LDL cholesterol, same blood pressure, same clean stress test. On paper their cardiovascular risk looks identical. Over the next decade, one of them has a heart attack and the other does not. A lot of what separates those two outcomes is invisible to a standard panel, and a meaningful slice of it can be captured by a single, cheap, widely…
This dispatch covers Your Cholesterol Is Fine and You Could Still Be on Fire Inside — The Inflammation Marker Almost No One Measures in the research research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 9 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Two people walk into the same clinic. Same age, same LDL cholesterol, same blood pressure, same clean stress test. On paper their cardiovascular risk looks identical. Over the next decade, one of them has a heart attack and the other does not.
A lot of what separates those two outcomes is invisible to a standard panel, and a meaningful slice of it can be captured by a single, cheap, widely available blood test that most adults have never had run: high-sensitivity C-reactive protein, written hs-CRP.
hs-CRP is a measure of low-grade, body-wide inflammation. It does not tell you where the inflammation is or why it is there, but it reliably tells you that it is there — and decades of research show that chronic, smoldering inflammation is one of the engines that turns cholesterol in an artery wall into a heart attack. The cholesterol is the fuel. Inflammation is part of the fire.
This article explains what hs-CRP is, why it predicts risk that cholesterol alone misses, why it is so rarely ordered, how to read the number, and what the science does and does not support. It is educational and not medical advice. But by the end you will understand why "your cholesterol looks great" and "your cardiovascular risk is fully assessed" are not the same sentence.
C-reactive protein is a molecule your liver produces in response to inflammation. When something triggers your immune system — an infection, an injury, a flare of an autoimmune condition — your liver pumps out CRP, levels can rise a hundredfold within a day or two, and then they fall again once the trigger resolves. That high-amplitude, short-term response is the "acute phase" version of CRP, and it is what an ordinary CRP test (often ordered when someone is acutely sick) is built to detect.
The version that matters for long-term health is different. High-sensitivity CRP is the same molecule measured with a far more precise assay — one sensitive enough to detect the small, persistent elevations that sit far below the range of acute illness. Those small elevations are the fingerprint of chronic low-grade inflammation: the kind that does not make you feel sick, produces no fever, throws no obvious symptom, and quietly persists for years.
That distinction is the whole point. A regular CRP test answers "are you acutely inflamed right now?" An hs-CRP test answers a much more useful question for someone who feels fine: "is your body carrying a low, constant inflammatory load that is shaping your long-term disease risk?"
For most of the twentieth century, heart disease was taught as essentially a plumbing problem: too much cholesterol in the blood, cholesterol builds up in the pipes, the pipes narrow, eventually one clogs. That model is not wrong, but it is incomplete — and the incompleteness is exactly where hs-CRP earns its place.
The modern understanding is that atherosclerosis is an inflammatory disease as much as a lipid one. The sequence looks roughly like this: LDL particles lodge in the artery wall; the immune system treats them as a threat; white blood cells move in; the wall becomes a site of chronic local inflammation; and the resulting plaque can either stabilize or become unstable. The dangerous plaques are frequently not the biggest ones — they are the inflamed, thin-capped ones that rupture, trigger a clot, and cause a heart attack with little warning. Inflammation is central to both how plaque forms and, critically, whether it stays quiet or blows.
hs-CRP is a downstream readout of that whole inflammatory milieu. It does not cause the damage by itself — it is more of a smoke detector than the fire — but it is a smoke detector that has been validated against hard outcomes in very large studies. People with higher hs-CRP have more heart attacks and strokes, and that association holds even after accounting for cholesterol, blood pressure, smoking, and diabetes. In other words, hs-CRP carries independent information. It tells you something LDL does not.
Two lines of evidence moved hs-CRP from interesting to clinically meaningful.
The first is the large body of prospective population research showing that hs-CRP predicts future cardiovascular events across men and women, and that it improves risk estimation when layered on top of traditional risk factors. This is why hs-CRP appears in major prevention guidelines as a "risk-enhancing" factor — a tiebreaker that can reclassify someone sitting in a gray zone of intermediate risk, helping clarify whether more aggressive prevention is warranted.
The second, and more striking, is the trial evidence that inflammation is not merely a marker but a target. The landmark JUPITER trial enrolled people who had normal or even low LDL cholesterol but elevated hs-CRP — exactly the population a cholesterol-only screen would wave through as low risk. Treating them with a statin substantially reduced cardiovascular events. Statins lower LDL, but they also lower inflammation, and JUPITER demonstrated that people flagged by inflammation alone benefited. Later trials went further: an anti-inflammatory therapy that did not touch cholesterol at all still reduced cardiovascular events in high-risk patients, providing some of the most direct evidence that inflammation itself contributes causally to the disease.
The practical upshot of that research is a concept worth knowing: residual inflammatory risk. Many people get their LDL beautifully controlled and still have events — and a major reason is that their inflammatory risk was never addressed because it was never measured. You cannot manage what you do not look at.
For cardiovascular risk stratification, hs-CRP is conventionally read in three bands (units are milligrams per liter, mg/L):
Those bands come from the American Heart Association and CDC consensus on using hs-CRP for cardiovascular risk, and they describe relative risk — your standing compared with others — not a diagnosis.
A few interpretation rules matter enormously, because they are where hs-CRP gets misread:
One reading is not enough. Because CRP spikes with any acute inflammation, a single elevated value can simply mean you were fighting a cold, recovering from a hard workout, nursing an injury, or coming off a poor night. Best practice is to measure hs-CRP when you are well, away from acute illness, and to confirm an elevation with a repeat test a couple of weeks later before drawing conclusions. A value taken while you are sick is close to meaningless for long-term risk.
Very high values are a different conversation. Levels well above the cardiovascular range (often cited as above roughly 10 mg/L) usually point to an active acute or significant inflammatory process — infection, injury, an autoimmune flare — rather than the low-grade chronic inflammation hs-CRP is being used to detect here. Those readings are a signal to look for an acute cause and recheck once it resolves, not to slot someone into a cardiovascular risk tier.
Context changes the meaning. Obesity, smoking, poor metabolic health, certain chronic conditions, and even hormonal factors all raise baseline hs-CRP. That is part of why it is informative — it integrates a lot of biology into one number — but it also means the value should be read alongside the rest of the picture, not in isolation.
If hs-CRP is cheap, widely available, guideline-acknowledged, and validated against hard outcomes, why has the average adult never had it run?
Several reasons converge. A standard "cholesterol check" is a lipid panel, and hs-CRP simply is not part of that default order — it has to be added deliberately. Because it is a non-specific marker, some clinicians are wary of ordering a test that flags a problem without naming its location, and a busy primary-care visit is not built for the nuance of "elevated, repeat in two weeks, interpret in context." And historically, prevention has been organized around cholesterol numbers, so a marker that lives outside the lipid panel gets crowded out of a short appointment.
None of those reasons make the information unimportant. They mostly explain why a useful, inexpensive number ends up invisible by default — and why two people with identical-looking panels can be carrying very different real risk.
It is worth being precise about the boundaries, because overclaiming is how good markers get discredited.
hs-CRP is good for: refining cardiovascular risk beyond what cholesterol alone shows; helping clarify decisions in the intermediate-risk gray zone; surfacing the "residual inflammatory risk" that a lipid-only view misses; and tracking a person's own inflammatory load over time when measured consistently.
hs-CRP is not: a diagnosis of any specific disease; a localizer that tells you where inflammation lives; a standalone reason to start any particular treatment; or a number to panic over from a single reading. It is one input — a genuinely informative one — into a fuller assessment.
And there is a constructive side that makes it worth knowing rather than fearing: unlike some genetically fixed markers, hs-CRP is responsive. Chronic inflammation is shaped by things that move — body composition, metabolic health, sleep, activity, smoking status, and overall load on the system. A number that can change is a number that can be a feedback signal, which is exactly what you want from a marker you intend to act on rather than just file away.
A clean lipid panel answers one question well: how much cholesterol fuel is in circulation. It is silent on a second question that matters just as much: how inflamed is the wall that fuel is landing in. hs-CRP is one of the few cheap, validated ways to ask that second question — and the research is clear that the answer carries information a cholesterol number cannot supply, that it reclassifies real people in the risk gray zone, and that the inflammatory risk it captures is one of the most common reasons "my cholesterol was fine" precedes a cardiac event.
You do not get a complete read on cardiovascular risk by measuring the fuel and ignoring the fire. A thorough panel asks both questions. Most panels only ask one.
This article is educational and does not constitute medical advice. Biomarker values should be interpreted by a qualified clinician in the context of your full history. If you want a panel that looks past the standard cholesterol check — including inflammatory and metabolic markers most physicals skip — that is exactly the gap 1836 was built to close.
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.